Alembic Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE901L01018
  • NSEID: APLLTD
  • BSEID: 533573
INR
894.60
-7.6 (-0.84%)
BSENSE

Dec 05

BSE+NSE Vol: 10.55 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 807696,
    "name": "Alembic Pharma",
    "stock_name": "Alembic Pharma",
    "full_name": "Alembic Pharmaceuticals Ltd.",
    "name_url": "stocks-analysis/alembic-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "894.60",
    "chg": -7.6,
    "chgp": "-0.84%",
    "dir": -1,
    "prev_price": "902.20",
    "mcapval": "17,584.54 Cr",
    "mcap": "Small Cap",
    "scripcode": 533573,
    "symbol": "APLLTD",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE901L01018",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "10.55 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/alembic-pharma-807696-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-bearish-momentum-amid-technical-downgrade-3740237",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AlembicPharmace_technicaldot_3740237.png",
        "date": "2025-12-02 08:08:59",
        "description": "Alembic Pharmaceuticals is currently navigating a phase marked by a discernible shift in technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent assessment changes highlight a transition in key technical indicators, signalling a more cautious outlook for the stock amid broader market fluctuations."
      },
      {
        "title": "Alembic Pharmaceuticals: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/alembic-pharmaceuticals-downgraded-to-sell-amid-technical-weakness-and-growth-concerns-3730418",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_mojoScore_3730418.png",
        "date": "2025-11-26 08:18:57",
        "description": "Alembic Pharmaceuticals has experienced a revision in its market assessment following a detailed review of its financial performance, valuation metrics, and technical indicators. The pharmaceutical company’s recent quarterly results, long-term growth trends, and evolving technical signals have collectively influenced the updated evaluation of its investment profile."
      },
      {
        "title": "Alembic Pharmaceuticals: Technical Momentum Shifts Signal Market Caution",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-faces-mildly-bearish-momentum-amid-technical-downgrade-3730303",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3730303.png",
        "date": "2025-11-26 08:07:05",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, with recent evaluation adjustments indicating a transition from a sideways trend to a mildly bearish stance. This development is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and volume-based metrics, suggesting a nuanced market outlook for the pharmaceutical sector player."
      },
      {
        "title": "How has been the historical performance of Alembic Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-alembic-pharma-3729609",
        "imagepath": "",
        "date": "2025-11-25 22:56:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.</p>\n<p>Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres..."
      },
      {
        "title": "Alembic Pharmaceuticals Forms Death Cross Signalling Potential Bearish Trend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-forms-death-cross-signalling-potential-bearish-trend-3729502",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_dealthcross_3729502.png",
        "date": "2025-11-25 18:20:21",
        "description": "Alembic Pharmaceuticals has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development is often interpreted as a signal of weakening momentum and potential long-term bearishness for the stock, raising concerns among investors about the company’s near-term trend."
      },
      {
        "title": "Alembic Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3727568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3727568.png",
        "date": "2025-11-25 08:10:24",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend. This change reflects a complex interplay of technical indicators, including MACD, RSI, moving averages, and volume-based metrics, which together paint a nuanced picture of the stock’s near-term market behaviour."
      },
      {
        "title": "Is Alembic Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-alembic-pharma-technically-bullish-or-bearish-3713916",
        "imagepath": "",
        "date": "2025-11-19 08:15:51",
        "description": "As of 18 November 2025, the technical trend for Alembic Pharma has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, supported by the weekly MACD and KST both indicating bearish signals, along with the Dow Theory and Bollinger Bands also showing mildly bearish trends. The daily moving averages are mildly bullish, but this is outweighed by the overall bearish indicators in the weekly and monthly time frames. The stock has underperformed against the Sensex in various time frames, further reinforcing the bearish outlook...."
      },
      {
        "title": "Alembic Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/alembic-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3714298",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AlembicPharmace_technicaldot_3714298.png",
        "date": "2025-11-19 08:07:51",
        "description": "Alembic Pharmaceuticals has experienced a notable shift in its technical parameters, reflecting a nuanced change in price momentum and market sentiment. Recent data indicates a transition from a mildly bullish to a mildly bearish technical trend, underscoring evolving investor perspectives within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Alembic Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-alembic-pharma-technically-bullish-or-bearish-3710324",
        "imagepath": "",
        "date": "2025-11-18 08:31:48",
        "description": "As of 17 November 2025, the technical trend has changed from mildly bearish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating bullish momentum. However, the weekly and monthly MACD, KST, and Dow Theory remain bearish to mildly bearish, suggesting caution. The RSI shows no signals, and Bollinger Bands are sideways on the weekly chart, indicating a lack of strong directional movement. Overall, while there are bullish signs on the daily timeframe, the broader weekly and monthly indicators suggest a mixed outlook...."
      }
    ],
    "total": 5253,
    "sid": "807696",
    "stock_news_url": "https://www.marketsmojo.com/news/alembic-pharmaceuticals-807696"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "01-Dec-2025",
      "details": "Resignation of Senior Managerial Personnel",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "15-Nov-2025",
      "details": "Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP 30 mg 60 mg 90 mg and 120 mg",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "13-Nov-2025",
      "details": "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dexlansoprazole Delayed-Release Capsules 30mg and 60 mg.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Alembic Pharmaceuticals Ltd. has declared <strong>550%</strong> dividend, ex-date: 29 Jul 25",
          "dt": "2025-07-29",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views

How has been the historical performance of Alembic Pharma?

2025-11-25 22:56:06

Revenue and Profit Trends

Over the seven-year period ending March 2025, Alembic Pharma’s net sales have shown consistent growth, increasing from ₹3,935 crores in 2019 to ₹6,672 crores in 2025. This represents a compound annual growth rate (CAGR) of approximately 10.5%, reflecting the company’s expanding market presence and product portfolio. Total operating income mirrors this trend, as other operating income remained nil throughout the period.

Operating profit before depreciation and interest (PBDIT) excluding other income exhibited volatility, peaking at ₹1,480 crores in 2021 before moderating to ₹1,008 crores in 2025. The operating profit margin (excluding other income) declined from a high of 27.45% in 2021 to 15.11% in 2025, indicating rising costs or pricing pres...

Read More
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Change in Management

01-Dec-2025 | Source : BSE

Resignation of Senior Managerial Personnel

Announcement under Regulation 30 (LODR)-Press Release / Media Release

15-Nov-2025 | Source : BSE

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Diltiazem Hydrochloride Tablets USP 30 mg 60 mg 90 mg and 120 mg

Announcement under Regulation 30 (LODR)-Press Release / Media Release

13-Nov-2025 | Source : BSE

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Dexlansoprazole Delayed-Release Capsules 30mg and 60 mg.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Alembic Pharmaceuticals Ltd. has declared 550% dividend, ex-date: 29 Jul 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available